Taking a GLP-1 and Hormone Therapy at the Same Time

The short version

A large number of women are on both of these at once, and almost nothing has been written about the combination. This page is about the interaction — whether hormone therapy changes what a GLP-1 does, and whether a GLP-1 changes anything about hormone therapy. It is not about menopausal weight itself, which is covered on GLP-1s after menopause and, for the still-cycling years, on perimenopausal weight.

The honest headline: one retrospective cohort has asked the question directly. No randomized trial has. That single study found women on hormone therapy lost more weight on semaglutide — and the reasons to be careful with that finding are more instructive than the finding itself.

What hormone therapy is actually for

Worth stating plainly, because the rest of this page gets misread without it. The North American Menopause Society's 2022 position statement puts the indications as bothersome vasomotor symptoms and prevention of bone loss, with a benefit-risk balance it calls favorable for women under 60 or within 10 years of menopause onset and no contraindications, and less favorable when therapy starts more than 10 years out or after 60, because the absolute risks of coronary heart disease, stroke, venous thromboembolism and dementia are higher in that group¹. Weight loss is not on that list. Hormone therapy is not a weight-loss treatment and nothing below should be read as arguing that it is.

The mirror-image fear is also worth retiring. A Cochrane review of randomized trials found no significant difference in weight gain between women on unopposed estrogen and non-users (0.66 kg, 95% CI −0.62 to 1.93), and none between combined estrogen-progestogen users and non-users (−0.47 kg, 95% CI −1.63 to 0.69), concluding that these regimens do not cause weight gain beyond what is normally gained at menopause². Both confidence intervals cross zero in both directions. That review is from 2000, so it long predates current formulations — but the specific fear it tested, that hormone therapy makes you gain weight, has never had good support.

The one study that asked the question

A 2024 retrospective cohort in Menopause, from the Mayo Clinic's obesity program, followed postmenopausal women treated with semaglutide for overweight or obesity for at least three months, and split them by whether they were also using menopausal hormone therapy³.

Figures are total body weight loss percentage. The gap held at every timepoint, more women on hormone therapy reached both the 5% and 10% thresholds at twelve months, and the association survived adjustment for potential confounders. Both groups improved on glucose, blood pressure and lipids.

Why that is much weaker than it looks

Four things, and they are the reason this page exists rather than a headline.

Sixteen women. The hormone-therapy arm is sixteen people. An estimate from a group that size is compatible with a wide range of true effects, including none.

The groups were not alike to begin with. Mean BMI was 36 in the hormone-therapy group against 39 in the other, and dyslipidemia and depression were both more common among the women not on hormone therapy. Starting lighter and with fewer competing conditions predicts a better weight-loss response on its own.

Nobody was randomized to hormone therapy. Women who take it differ systematically from women who do not — in how they engage with healthcare, in what their clinician offered them, and in what they could tolerate. That is confounding by indication, and statistical adjustment reduces it rather than removing it.

It is one center, looking backward. A retrospective chart review generates a hypothesis. It does not test one.

The plausible mechanism is real enough to keep the question alive: a systematic review of ten studies found estrogen administration raised resting energy expenditure by up to +222 kcal per day in the menopausal-hormone-therapy setting, and up to +208 kcal in the contraceptive setting⁴. A higher resting burn is a coherent explanation for a larger deficit at the same dose. Plausibility is not evidence of effect, but it does mean the cohort finding is not obviously spurious.

What nobody has tested

No trial has randomized women to a GLP-1 with or without hormone therapy, in either direction. A 2026 scoping review of GLP-1 receptor agonists in menopausal and postmenopausal women reports that effects in this group "are not well characterized and may differ from other patient populations, given their different hormone profiles," finds the literature on central adiposity, vasomotor symptoms and cardiovascular markers limited, and closes by asking for larger studies⁵.

So the practical questions — whether to start both at once or stagger them, whether hormone therapy protects any of the lean mass a GLP-1 costs you, whether a GLP-1 changes hormone-therapy dosing — have no published answers at all. Coordination between whoever prescribes each one is a conversation between clinicians, not a protocol either can look up.

Two things do follow. Do not start hormone therapy in order to lose weight; that is not what the indications support and one small cohort does not change them. And do not stop hormone therapy you were prescribed for symptoms in order to "let the GLP-1 work" — nothing here supports that, and the only direct evidence points the other way. Vaginal estrogen is a separate question again, acting on tissue rather than systemically; that sits with vaginal dryness and irritation on a GLP-1.

Where this sits on the evidence scale

Hormone therapy does not cause weight gain: reasonably strong, but dated. A Cochrane review of randomized trials, with confidence intervals comfortably spanning zero. Old formulations.

Hormone therapy improves the weight-loss response to semaglutide: very low. One retrospective cohort, sixteen exposed women, groups differing at baseline in exactly the directions that would produce this result anyway. Interesting; not actionable.

The mechanism: moderate, and indirect. Estrogen measurably raises resting energy expenditure across ten studies. That supports plausibility, not a clinical effect.

Everything else about the combination: no evidence. Not weak data — none. A 2026 review of this exact population searched for it and asked for trials to be run.